Dyslipidemia US Drug Forecast and Market Analysis to 2023 Prices from USD $4995

16:52 EST 1 Dec 2016 | BioPortfolio Reports

Dyslipidemia US Drug Forecast and Market Analysis to 2023


GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales 72% and $4.4bn in generic sales 28%. GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales $26.9bn and 29% to generic drug sales $11.0bn. The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce lowdensity lipoprotein cholesterol LDLC and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipidmodulating drugs, such as Zetia ezetimibe, the fibrates, bile acid sequestrants, omega3 fish oil agents, and raredisease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 PCSK9 biologics and the cholesteryl ester transfer protein CETP inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.

Of the 8MM forecast for dyslipidemia, the US market exceeds the other seven countries in sales for every class and brand of drug by a significant margin. . In the 2013 base year, the global market size for dyslipidemia was $15.4 billion, approximately 65% of which could be attributed to drug sales in the US.

*This is an ondemand report and will be delivered within 24 hrs. excluding weekends of the purchase.


Overview of Dyslipidemia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 20132023.
Analysis of the impact of key events as well the drivers and restraints affecting the US Dyslipidemia market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Dyslipidemia.
Effectively plan your MA and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and indepth analysis of drug performance
Obtain sales forecast for drugs from 20132023 in the US.

Original Article: Dyslipidemia US Drug Forecast and Market Analysis to 2023 Prices from USD $4995


More From BioPortfolio on "Dyslipidemia US Drug Forecast and Market Analysis to 2023 Prices from USD $4995"

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...